What We're Looking For From Summit Therapeutics PLC (ADR) (SMMT)
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) is running up this week on an update relating to its lead C. Difficile infection asset, Ridinilazole.
February 2nd, 2017 - News Stock Analysis
October 4th, 2016 - News
June 21st, 2016 - News Stock Analysis
December 10th, 2015 - Hedge Funds News
Returns since its inception in May 2014 (through February 19th, 2025)